+

WO2004027066A3 - Protéine recombinante chimérique et diagnostic in vitro du hiv - Google Patents

Protéine recombinante chimérique et diagnostic in vitro du hiv Download PDF

Info

Publication number
WO2004027066A3
WO2004027066A3 PCT/FR2003/002712 FR0302712W WO2004027066A3 WO 2004027066 A3 WO2004027066 A3 WO 2004027066A3 FR 0302712 W FR0302712 W FR 0302712W WO 2004027066 A3 WO2004027066 A3 WO 2004027066A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
recombinant protein
glycoprotein
group
vitro diagnosis
Prior art date
Application number
PCT/FR2003/002712
Other languages
English (en)
Other versions
WO2004027066A2 (fr
Inventor
Odile Letourneur
Original Assignee
Biomerieux Sa
Odile Letourneur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux Sa, Odile Letourneur filed Critical Biomerieux Sa
Priority to EP03773778A priority Critical patent/EP1539963A2/fr
Priority to US10/526,765 priority patent/US20060121049A1/en
Priority to AU2003282159A priority patent/AU2003282159A1/en
Publication of WO2004027066A2 publication Critical patent/WO2004027066A2/fr
Publication of WO2004027066A3 publication Critical patent/WO2004027066A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un ADN recombinant codant une protéine recombinante chimérique comprenant - au moins deux premiers fragments nucléotidiques codant chacun une région épitopique du virus HIV- 1 de groupe M ou de groupe O ou le virus HIV-2 - au moins un deuxième fragment nucléotidique codant une région de liaison, - au moins un troisième fragment nucléotidique codant une région de fixation caractérisé en ce que chaque premier fragment nucléotidique code au moins une région immunodominante de la glycoprotéine gp 120 d'HIV-1, de la glycoprotéine gp 41 d'HIV-1 de groupe M, de la glycoprotéine gp 41 d'HIV-1 de groupe O ou de la glycoprotéine gp 36 d'HIV-2. L'invention concerne également une protéine chimérique recombinante codée par l'ADN défini ci dessus, ainsi que l'utilisation dudit ADN et/ou de ladite protéine recombinante pour le diagnostic in vitro.
PCT/FR2003/002712 2002-09-17 2003-09-15 Protéine recombinante chimérique et diagnostic in vitro du hiv WO2004027066A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03773778A EP1539963A2 (fr) 2002-09-17 2003-09-15 Proteine recombinante chimerique et diagnostic in vitro du hiv
US10/526,765 US20060121049A1 (en) 2002-09-17 2003-09-15 Chimeric recombinant protein and in vitro diagnosis
AU2003282159A AU2003282159A1 (en) 2002-09-17 2003-09-15 Chimeric recombinant protein and in vitro diagnosis of hiv

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0211485A FR2844519A1 (fr) 2002-09-17 2002-09-17 Proteine recombinante chimerique et diagnostic in vitro
FR02/11485 2002-09-17

Publications (2)

Publication Number Publication Date
WO2004027066A2 WO2004027066A2 (fr) 2004-04-01
WO2004027066A3 true WO2004027066A3 (fr) 2004-05-21

Family

ID=31897433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002712 WO2004027066A2 (fr) 2002-09-17 2003-09-15 Protéine recombinante chimérique et diagnostic in vitro du hiv

Country Status (5)

Country Link
US (1) US20060121049A1 (fr)
EP (1) EP1539963A2 (fr)
AU (1) AU2003282159A1 (fr)
FR (1) FR2844519A1 (fr)
WO (1) WO2004027066A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084021A2 (fr) * 2006-01-17 2007-07-26 Instituto De Medicina Molecular Compositions et procédés de diagnostic de l'infection par vih-2
FR3067814A1 (fr) * 2017-06-20 2018-12-21 Biomerieux Procede d'application, sur un support solide, d'au moins un partenaire de liaison a une molecule
WO2019018402A2 (fr) * 2017-07-17 2019-01-24 Janssen Biotech, Inc. Régions de liaison à un antigène dirigées contre les domaines de la fibronectine de type iii et leurs procédés d'utilisation
CA3097193A1 (fr) 2018-05-08 2019-11-14 Phanes Therapeutics, Inc. Anticorps anti-dll3 et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0577894A1 (fr) * 1992-06-17 1994-01-12 Korea Green Cross Corporation Conception, construction et expression de protéines chimériques pour le développement de vaccins et de réactifs diagnostiques
WO1995033206A1 (fr) * 1994-05-31 1995-12-07 Abbott Laboratories Detection de differents genotypes de vih utilisant un immunodosage modifie par un peptide synthetique
WO1999009410A2 (fr) * 1997-08-15 1999-02-25 Abbott Laboratories Titrage rapide pour la detection et la differenciation simultanees d'anticorps contre le vih
DE10106295C1 (de) * 2001-02-02 2002-08-22 Gaifar German American Inst Fo Protein mit mehreren Antigen-Epitop-Sequenzen, welches immobilisiert ist

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2172305A1 (fr) * 1995-03-30 1996-10-01 Muneo Aoyama Peptide antigenique multiple, renfermant au moins deux peptides associes du virus de l'hepatite c

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0577894A1 (fr) * 1992-06-17 1994-01-12 Korea Green Cross Corporation Conception, construction et expression de protéines chimériques pour le développement de vaccins et de réactifs diagnostiques
WO1995033206A1 (fr) * 1994-05-31 1995-12-07 Abbott Laboratories Detection de differents genotypes de vih utilisant un immunodosage modifie par un peptide synthetique
WO1999009410A2 (fr) * 1997-08-15 1999-02-25 Abbott Laboratories Titrage rapide pour la detection et la differenciation simultanees d'anticorps contre le vih
DE10106295C1 (de) * 2001-02-02 2002-08-22 Gaifar German American Inst Fo Protein mit mehreren Antigen-Epitop-Sequenzen, welches immobilisiert ist

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAN, B. ET AL.: "The use of a chimera HIV-1/HIV-2 envelope protein for immunodiagnosis of hiv infection : Its expression and purification in E. coli by use of translation initiation site within HIV-1 env gene", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 46, no. 3, October 1998 (1998-10-01), ORLANDO, FL US, pages 607 - 617, XP008021044 *
SHIN S.Y. ET AL.: "The use of multiple antigenic peptide (MAP) in the immunodiagnosis of human deficiency virus infection", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 43, no. 4, November 1997 (1997-11-01), ORLANDO, FL US, pages 713 - 721, XP008021043 *
VALLARI ET AL.: "Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 Group O and HIV-2", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 36, no. 12, December 1998 (1998-12-01), pages 3657 - 3661, XP002252066 *

Also Published As

Publication number Publication date
EP1539963A2 (fr) 2005-06-15
AU2003282159A1 (en) 2004-04-08
AU2003282159A8 (en) 2004-04-08
FR2844519A1 (fr) 2004-03-19
US20060121049A1 (en) 2006-06-08
WO2004027066A2 (fr) 2004-04-01

Similar Documents

Publication Publication Date Title
IL202249A (en) Nucleic Acids Encoders Human Immunodeficiency Strange Type 1 (HIV – 1) Group M Consensus Envelope Glycoproteins
AU5827800A (en) Fabrication of beta-pleated sheet proteins with specific binding properties
DE69535125D1 (de) Impstoff gegen felines immunodefizienz-virus
MY145614A (en) Vaccine
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
WO1999004011A3 (fr) Antigenes du groupe o du vih-1 et leurs utilisations
WO2002038792A3 (fr) Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)
AU5322800A (en) Cloned genone of infectious hepatitis c virus of genotype 2a and uses thereof
WO2004027066A3 (fr) Protéine recombinante chimérique et diagnostic in vitro du hiv
WO2002022663A3 (fr) Retrovirus resistant au stress
WO2003089571A3 (fr) Genes extrait de ehrlichia canis et vaccins contre cette bacterie
MXPA04002103A (es) Una proteina de union a caspasa-8, su preparacion y uso.
ES2073777T3 (es) Inhibicion de la replicacion virica.
PT1383796E (pt) Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações
WO1998042847A3 (fr) Proteines a capside principale de papillomavirus et leur utilisation a des fins de diagnostic, de therapie et de vaccination
WO2002090501A3 (fr) Vecteurs dont la replication, l'immunogenicite et/ou la pathogenicite sont regulees par le promoteur du stress et utilisation de ceux-ci
WO2002038769A3 (fr) Sequences adn expressionnelles codant pour hpv 16-l1 et hpv 16-l2 optimises eukaryotiques
WO2002034909A3 (fr) Chimere de fragments de proteines synthetisee et ses methodes d'utilisation
WO2004053052A3 (fr) Procede de determination de la structure primaire du messager arn codant pour l'endooligopeptidase a (heopa) [af217798]... humaine recombinante
IL145279A0 (en) Antibodies against caspase-8, their preparation and use
AU2002341238A1 (en) Diabetic model
WO2004111249A3 (fr) Produits de synthese proteiques renfermant des sites de reconnaissance de la caspase
EP0854186A3 (fr) Gène de division cellulaire DivIB de Staphylococcus aureus
IT1286307B1 (it) Virus mixomatoso ricombinante, suo impiego per la produzione di un vaccino e relativo vaccino.
EP0997529A3 (fr) Souche FIV-141 du virus de l'immunodéficience féline et ses utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003773778

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006121049

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10526765

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003773778

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10526765

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载